The attenuated African swine fever vaccine HLJ/18-7GD provides protection against emerging prevalent genotype II variants in China

Zilong Wang,Jiwen Zhang,Fang Li,Zhenjiang Zhang,Weiye Chen,Xianfeng Zhang,Encheng Sun,Yuanmao Zhu,Renqiang Liu,Xijun He,Zhigao Bu,Dongming Zhao

DOI: https://doi.org/10.1080/22221751.2023.2300464

2024-01-24

Emerging Microbes & Infections

Abstract:Genetic changes have occurred in the genomes of prevalent African swine fever viruses (ASFVs) in the field in China, which may change their antigenic properties and result in immune escape. There is usually poor cross-protection between heterogonous isolates, and, therefore, it is important to test the cross-protection of the live attenuated ASFV vaccines against current prevalent heterogonous isolates. In this study, we evaluated the protective efficacy of the ASFV vaccine candidate HLJ/18-7GD against emerging isolates. HLJ/18-7GD provided protection against a highly virulent variant and a lower lethal isolate, both derived from genotype II Georgia07-like ASFV and isolated in 2020. HLJ/18-7GD vaccination prevented pigs from developing ASF-specific clinical signs and death, decreased viral shedding via the oral and rectal routes, and suppressed viral replication after challenges. However, HLJ/18-7GD vaccination did not provide solid cross-protection against genotype I NH/P68-like ASFV challenge in pigs. HLJ/18-7GD vaccination thus shows great promise as an alternative strategy for preventing and controlling genotype II ASFVs, but vaccines providing cross-protection against different ASFV genotypes may be needed in China.

immunology,infectious diseases,microbiology

What problem does this paper attempt to address?

The paper mainly addresses the following key issues:

1. **Background and Challenges**: African Swine Fever (ASF) is a highly contagious disease caused by the African Swine Fever Virus (ASFV), posing a threat to global food security. Since the emergence of ASFV genotype II in China in 2018, the virus has continued to evolve, leading to antigenic changes that may trigger immune escape. Additionally, there is often a lack of cross-protection between different ASFV isolates.

2. **Research Objectives**: To evaluate the protective efficacy of an attenuated live vaccine candidate HLJ/18-7GD against the currently prevalent ASFV genotype II variants in China. The HLJ/18-7GD vaccine is based on the highly pathogenic ASFV isolate HLJ/18, which was the earliest to appear in China, and was attenuated by deleting seven genes.

3. **Experimental Design and Results**:
- Researchers assessed the protective efficacy of the HLJ/18-7GD vaccine against two ASFV genotype II variants: a highly pathogenic variant HuB/628/20 and a less lethal variant HLJ/HRB1/20.
- The experimental results showed that the HLJ/18-7GD vaccine effectively protected pigs from infection by these two genotype II variants, reducing the occurrence of clinical symptoms, decreasing the amount of virus shed from the mouth and rectum, and inhibiting viral replication within the body.
- However, when challenged with ASFV genotype I (such as SD/DY-I/21), the HLJ/18-7GD vaccine failed to provide effective cross-protection, although it did alleviate clinical symptoms to some extent.

4. **Conclusion and Outlook**: The HLJ/18-7GD vaccine shows great potential as an effective strategy for the prevention and control of ASFV genotype II. However, for China, it may be necessary to develop vaccines that can provide cross-protection against different ASFV genotypes.